Current Treatment Strategies for Clozapine-Induced Sialorrhea

  title={Current Treatment Strategies for Clozapine-Induced Sialorrhea},
  author={Angela M Bird and Tawny L Smith and Amy Walton},
  journal={Annals of Pharmacotherapy},
  pages={667 - 675}
Objective: To provide an understanding of the underlying pathophysiology and current treatment options for clozapine-induced sialorrhea. Data Sources: Literature was retrieved through MEDLINE (1977-February 2011) using the key search terms clozapine, sialorrhea, hypersalivation, drooling, and treatment. In addition, reference citations from identified publications were reviewed. Study Selection and Data Extraction: All articles published in English identified from the data source were evaluated… 

Tables from this paper

Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis

Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events, and Caution should be exercised when using propantheline given its increased risk of constipation.

A systematic review of non-invasive and invasive sialorrhoea management.

It is proposed that management strategies follow a multidisciplinary approach to meet the diverse needs of patients to improve quality of life of patients and provide formative scope to the development of an integrated care pathway.

Glycopyrrolate for treatment of clozapine-induced sialorrhea in adults.

Glycopyrrolate is an antimuscarinic agent that can be used preoperatively to inhibit drooling and excessive secretions of the respiratory tract to treat clozapine-induced sialorrhea.

Immediate-Release Oxybutynin for the Treatment of Clozapine-Induced Sialorrhea

This is the first report of immediate-release oxybutynin successfully reducing clozapine-induced sialorrhea, and if oxy butynin is considered for this indication, use of the immediate- release formulation seems prudent.

The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Glycopyrrolate seemed to be a tolerable anticholinergic agent in the treatment of clozapine-associated sialorrhea, and was not superior to placebo, whereas 2 mg showed a significant clinical improvement of nocturnal sIALorrhea compared with placebo.

Low-dose Amisulpride for Debilitating Clozapine-induced Sialorrhea: Case Series and Review of Literature

Current series of five subjects who developed CIS that responded poorly to anticholinergic drugs found drastic improvement in daytime and nocturnal CIS with very low-dose (50-100 mg/day) of amisulpride, which may provide strong ameliorating effect on CIS.

Reporting Patterns of Sialorrhea Comparing Users of Clozapine to Users of Other Antipsychotics

Sialorrhea was reported almost 4 times more frequently with clozapine use than with other antipsychotic use and was reported 8 times more often by patients than by health care professionals, underlining the importance to incorporate sialorrhee into the shared decision process when commencing clozAPine therapy.

Management of clozapine-induced sialorrhoea

Sialorrhoea (hypersalivation) is a common adverse effect of clozapine, and Anticholinergic medications are commonly prescribed for it, but they have limited effect and can worsen constipation.

Association Between N-Desmethylclozapine and Clozapine-Induced Sialorrhea: Involvement of Increased Nocturnal Salivary Secretion via Muscarinic Receptors by N-Desmethylclozapine

N-desmethylclozapine, a metabolite of clozAPine, is implicated in CIS by increasing nocturnal salivation via the muscarinic receptors and that oral administration of clazapine at 100 mg/kg once daily for 7 days to rat is the optimum method for establishing the new animal model reflecting the clinical scenario of CIS.

Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): a feasibility study

The feasibility study demonstrated that a trial of alternative medications in the treatment of CIH is feasible; patients were willing to be randomised to the trial and retention rate was high.



Potential use of ipatropium bromide for the treatment of clozapine‐induced hypersalivation: a preliminary report

This case series demonstrates the possible utility of intranasal IPB for clozapine‐induced sialorrhea and shows only qualitative differences in salivation values and large controlled‐comparative trials are needed.

Intraoral Application of Atropine Sulfate Ophthalmic Solution for Clozapine-Induced Sialorrhea

A case in which oral use of an atropine sulfate ophthalmic solution resulted in amelioration of clozapine-induced sialorrhea, an atypical antipsychotic agent considered to be highly efficacious with a low incidence of extrapyramidal side effects is presented.

Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea

Like for PD, botulinum toxin type B represents an effective and safe treatment for neuroleptic-induced sialorrhea with a treatment effect of 8 to 16 weeks.

Botulinum toxin as an effective treatment of clozapine-induced hypersalivation

The patient serves to alert clinicians to the frequent problem of drug-induced sialorrhea and suggests that BTX injections should be considered as an effective and safe treatment for hypersalivation in psychiatric patients treated with clozapine.

Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study.

Glycopyrrolate in doses of 0.10 mg/kg per dose is effective at controlling sialorrhea in children with developmental disabilities and even at low doses, 20% of children may exhibit adverse effects severe enough to require discontinuation.

Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study.

The findings support reports of the beneficial effect ofClozapine-sulpiride combination therapy and suggest that sulpiride addition may contribute to the amelioration of clozapines-induced hypersalivation.

Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea.

A 35-year-old man with a diagnosis of paranoid schizophrenia for the past 10 years was initiated on clozapine as he was treatment resistant and developed troublesome sialorrhoea, which occurred during both night and day, and despite amitriptyline’s potential to cause sedation, his nocturnal enuresis improved.

Comparative Efficacy and Tolerability of Benzatropine and Terazosin in the Treatment of Hypersalivation Secondary to Clozapine

The results of this retrospective study demonstrated that terazosin was an effective and well tolerated drug in the management of a very common adverse effect of clozapine therapy, namely, hypersalivation.

Amisulpride treatment for clozapine-induced sialorrhea.

Moclobemide Treatment of Clozapine-Induced Hypersalivation: Pilot Open Study

It is assumed that moclobemide can be another additional and safe medication for the treatment of CIHS; however, more data, based on controlled studies, are needed.